Home›Companies›Biotech & Pharma›Serimmune

Serimmune Inc.

Updated Oct 27, 2026·Latest SEC filing Nov 15, 2023·Suggest an edit

About Serimmune

Serimmune is a private company based in Goleta, California. It has reported $27,467,062 raised in four offerings on Form D since January 2017. Its chief executive is Malek Faham.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Oct 31, 2023Aug 11, 2021amended Nov 15, 2023$11,512,176of $16.5M target2$5.7MDebt, Convertible Promissory Notes and the Equity Securities issuable upon conversion of such NotesRule 506(b)Form D/A ↗4 earlier filings
Aug 27, 2020Sep 11, 2020$12,048,253of $23.3M target7$1.7MEquityRule 506(b)Form D ↗
May 22, 2019Jun 5, 2019$1,406,111of $7.0M target5$281KDebt, Convertible Promissory Notes and the Equity Securities issuable upon conversion of such Notes.Rule 506(b)Form D ↗
Dec 21, 2016Jan 5, 2017$2,500,522of $8.0M target7$357KEquityRule 506(b)Form D ↗
Total, four offerings$27,467,062

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Serimmune's Form D filed Nov 15, 2023.

MF
Malek Faham
Chief Executive Officer and director
KL
BW
Bill Welch
Director

Earlier filings also listed Stephen Kujawa (executive officer, last listed Sep 2020), Patrick Daugherty (executive officer and director, last listed Sep 2020), Noah Nasser (chief executive officer and director, last listed Sep 2020), Kristin Loomis (director, last listed Sep 2020), John Shon (executive officer, last listed Sep 2020) and Jaymie Sawyer (executive officer, last listed Sep 2020).

Sources

  1. SECSerimmune Inc. Form D/A, filed Aug 21, 2023
  2. SECSerimmune Inc. Form D/A, filed Dec 1, 2022
  3. SECSerimmune Inc. Form D/A, filed Jul 12, 2022
  4. SECSerimmune Inc. Form D, filed Aug 11, 2021
  5. SECSerimmune Inc. filing history